Last updated on July 2020

Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Advancing RMS Patients.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple Sclerosis | Relapsing MS | Advancing Multiple Sclerosis
  • Age: Between 18 - 65 Years
  • Gender: Male or Female

Key Inclusion Criteria:

  1. Signed informed consent must be obtained prior to participation in the study.
  2. Male or female aged 18 to 65 years (inclusive) at screening
  3. Patients with advancing RMS as defined by the principal investigator
  4. Prior history of relapsing MS (RMS), with or without progressive features, according to the 2010 Revised McDonald or Lublin criteria (Lublin et al, 2013)
  5. EDSS score of >2.0 to 6.5 (inclusive)
  6. Having been continuously treated with oral or injectable RMS DMTs

Key Exclusion criteria:

  1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  2. Patients with any medically unstable condition as determine by the investigator.
  3. History of hypersensitivity to the study drug or to drugs of similar chemical classes.

Other protocol-defined inclusion/exclusion criteria may apply.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.